Oncolytic viruses as novel anticancer agents: turning one scourge against another

Bibliography

• ADLER R, GLORIOSO JC, LEVINE M: Infection by herpes simplex virus and cells of nervous system origin: characterization of a non-permissive interaction. J. Gen. Vim]. (1978) 39(1):9–20.
   PubMed Web of Science ®Google Scholar
• MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252(5007):854–856.
   PubMed Web of Science ®Google Scholar
• ••Significant as marking the current trend of oncolytic uraltherapy.
   Google Scholar
• SHORT MP, CHOI BC, LEE JK, MALICK A, BREAKEFIELD XO, MARTUZA RL: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. (1990) 27(3):427–439.
   PubMed Web of Science ®Google Scholar
• TAKAMIYA Y, SHORT MP, MOOLTEN FL et al.: An experi-mental model of retrovirus gene therapy for malignant brain tumours. J. Neurosurg. (1993) 79(1) :104–110.
   PubMed Web of Science ®Google Scholar
• FOMSGAARD A, NIELSEN HV, KIRKBY N et al.: Induction of cytotoxic T-cell responses by gene gun DNA vaccina-tion with minigenes encoding influenza a virus HA and NP CTL-epitopes. Vaccine (1999) 18(7-8):681–691.
   PubMed Web of Science ®Google Scholar
• HORWITZ MS, SARVETNICK N: Viruses, host responses and autoimmunity. Immunol Rev. (1999) 169:241–253.
   PubMed Web of Science ®Google Scholar
• IRLIN IS, TER-GRIGOROV VS: Mechanism of regression of tumours induced by polyoma virus in rabbits. Nature (1968) 219(1601254–6.
   Web of Science ®Google Scholar
• BATLIWALLA FM, BATEMAN BA, SERRANO D et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T-cell repertoire. Mol. Med. (1998) 4(12):783–794.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, SIVANANDHAM M, BALCH CM et al.:Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. (1998) 187(0:69–77.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, SIVANANDHAM M, DITARANTO K et al:Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a Phase III, multi-institutional trial. Ann. Surg. (1997) 226(2):198–206.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, SIVANANDHAM M, WHOOLEY B, DITARANTO K, BARTOLUCCI AA: Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial. Ann. Surg. Oncol. (1996) 3(2):110–117.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, SIVANANDHAM M, BALCH CM et al: APhase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer (1995) 75(1):34–42.
   PubMed Web of Science ®Google Scholar
• BERTHIER-VERGNES 0, PORTOUKALIAN J, LEFTHERI-OTIS E, DORE JF: Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res. (1994) 54(9)2433–2439.
   Google Scholar
• CASSEL WA, MURRAY DR: A ten-year follow-up on stageII malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Merl. Oncol Tumour Pharmacother. (1992) 9(4):169–171.
   PubMedGoogle Scholar
• FREEDMAN RS, BOWEN JM, ATKINSON EN et al: Randomized comparison of viral oncolysate plus radiation and radiation alone in uterine cervix carcinoma. Am. J. Clin. Oncol. (1989) 12(3):244–250.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, BASH J, BARTOLUCCI A: Improvement in disease-free survival of melanoma patients in conjunc-tion with serologic response in a Phase Ia/Ib southeastern cancer study group trial of vaccinia melanoma oncolysate. Am. Surg. (1989) 55(0243–247.
   PubMed Web of Science ®Google Scholar
• CASSEL WA, MURRAY DR: Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate [letter]. Nat. Immun. Cell Growth Regul. (1988) 7(5-6):351–352.
   PubMedGoogle Scholar
• CASSEL WA, MURRAY DR, PHILLIPS HS: A Phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer (1983) 52(5):856–860.
   PubMed Web of Science ®Google Scholar
• CASSEL WA, MURRAS DR, TORBIN AH, OLKOWSKI ZL, MOORE ME: Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer (1977) 40(2):672–679.
   Google Scholar
• MURRAY DR, CASSEL WA, TORBIN AH, OLKOWSKI ZL, MOORE ME: Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer (1977) 40(2)680–686.
   Google Scholar
• WALLACK MK, STEPLEWSKI Z, KOPROWSKI H et al: A new approach in specific, active immunotherapy. Cancer (1977) 39(2):560–564.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, HAWKINS MJ, TSANG KY et al: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol (1999) 17(1)332–337.
   Google Scholar
• KAWAKITA M, RAO GS, RITCHEY JK et al: Effect of canarypox virus (alvac)-mediated cytokine expres-sion on murine prostate tumour growth. J. Natl. Cancer Inst. (1997) 89(6):428–436.
   PubMed Web of Science ®Google Scholar
• PUISIEUX I, ODIN L, POUJOL D et al.: Canarypox virus-mediated interleukin-12 gene transfer into murine mammary adenocarcinoma induces tumour suppres-sion and long-term antitumoural immunity. Hum. Gene Ther. (1998) 9(17):2481–92.
   PubMed Web of Science ®Google Scholar
• TODA M, RABKIN SD, KOJIMA H, MARTUZA RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumour immunity. Hum. Gene Ther. (1999) 10(3):385–393.
   PubMed Web of Science ®Google Scholar
• •Describes the use of oncolytic HSV to generate systemic anticancer immunity.
   Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumour immunity. Proc. Natl Acad. ScL USA (1993) 90(8)3539–3543.
   Google Scholar
• •Describes the used of transplantable tumour cell lines and GM-CSF effect.
   Google Scholar
• BLOOM ET, OSSORIO RC, BROSMAN SA: Cell-mediatedcytotoxicity against human bladder cancer. Int. 1 Cancer (1974) 14(3):326–334.
   Google Scholar
• CHAHLAVI A, RABKIN S, TODO T, SUNDARESAN P, MARTUZA R: Effect of prior exposure to herpes simplex virus 1 on viral vector- mediated tumour therapy in immunocompetent mice. Gene Ther. (1999) 6(10):1751–1758.
   PubMed Web of Science ®Google Scholar
• HERRLINGER U, KRAMM CM, ABOODY-GUTERMAN KS et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumours by a HSV-1 vector. Gene Ther. (1998) 5(6):809–819.
   PubMed Web of Science ®Google Scholar
• IKEDA K, ICHIKAWA T, WAKIMOTO H et al.: Oncolytic virus therapy of multiple tumours in the brain requires suppression of innate and elicited antiviral responses. Nature Med. (1999) 5(8):881–887.
   PubMed Web of Science ®Google Scholar
• •Significant advance in the understanding and manipulation of mechanisms involved in initial infection.
   Google Scholar
• LAQUERRE S, ARGNANI R, ANDERSON DB, ZUCCHINI S,MANSERVIGI R, GLORIOSO JC: Heparan sulphate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contribu-tions to virus attachment, penetration and cell-to-cell spread. 1 Vim]. (1998) 72(7):6119–6130.
   Google Scholar
• LAQUERRE S, ANDERSON DB, STOLZ DB, GLORIOSO JC:Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. 1 Virol. (1998) 72(12):9683–9697.
   Google Scholar
• •Describes engineered HSV targeted to specific cellular receptors.
   Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumour cells [see comments]. Science (1996) 274(5286)373–376.
   Google Scholar
• •Important paper as it outlines crucial experiments leading to the use of this virus in widespread clinical trials.
   Google Scholar
• CHASE M, CHUNG RY, CHIOCCA EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol. (1998) 16(5):444–448.
   PubMed Web of Science ®Google Scholar
• •Describes the combination of viral oncolysis and prodrug activation.
   Google Scholar
• STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PW: The molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. Embo. 1 (1998) 17(12)3351-3362.
   Google Scholar
• •A significant advance in the understanding of a mechanism of viral selectivity for tumours.
   Google Scholar
• MIYATAKE S, IYER A, MARTUZA RL, RABKIN SD: Transcriptional targeting of herpes simplex virus for cell-specific replication. 1 Virol. (1997) 71 (7):5124–5132.
   Google Scholar
• •Describes promoter targeting of HSV
   Google Scholar
• CHUNG RY, SAEKI Y, CHIOCCA EA: B-myb promoter retargeting of herpes simplex virus 734.5 gene-mediated virulence toward tumour and cycling cells.1 Virol. (1999) 73(9):7556–7564.
   Google Scholar
• •Describes promoter targeting of HSV replication.
   Google Scholar
• BLACKWELL JL, MILLER CR, DOUGLAS JT et al.: Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolar-yngol. Head Neck Surg. (1999) 125(8):856–863.
   PubMed Web of Science ®Google Scholar
• GONZALEZ R, VEREECQUE R, WICKHAM TJ et al.: Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Ther. (1999) 6(3):314–320.
   PubMed Web of Science ®Google Scholar
• DOUKAS J, HOGANSON DK, ONG M et al: Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB. 1 (1999) 13(10:1459-1466.
   Google Scholar
• •A paper important for outlining receptor-mediated targeting of tumours by viruses.
   Google Scholar
• GU DL, GONZALEZ AM, PRINTZ MA et al.: Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumour activity in mice. Cancer Res. (1999) 59(10:2608–2614.
   PubMed Web of Science ®Google Scholar
• •Describes retargeted adenoviruses.
   Google Scholar
• GOLDMAN CK, ROGERS BE, DOUGLAS JT et al: Targetedgene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. (1997) 57 (8):1447–1451.
   PubMed Web of Science ®Google Scholar
• TEODORO JG, BRANTON PE: Regulation of p53-dependent apoptosis, transcriptional repression and cell transformation by phosphorylation of the 55-kilodalton ElB protein of human adenovirus Type 5.j Virol. (1997) 71 (5):3620–3627.
   Google Scholar
• NEVELS M, RUBENWOLF S, SPRUSS T, WOLF H, DOBNER T: The adenovirus E4ORF6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumour suppressor function. Proc. Nati Acad. ScL USA (1997) 94(4):1206–1211.
   PubMed Web of Science ®Google Scholar
• HARADA JN, BERK AJ: p53-independent and -depen-dent requirements for E1B-55k in adenovirus Type 5 replication. I Virol. (1999) 73(7):5333–5344.
   PubMed Web of Science ®Google Scholar
• HALL AR, DIX BR, O'CARROLL SJ, BRAITHWAITE AW: p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]. Nature Med. (1998) 4 (9) :1068–1072.
   PubMed Web of Science ®Google Scholar
• O'REILLY LA, HUANG DC, STRASSER A: The cell death inhibitor bc1-2 and its homologues influence control of cell cycle entry. Embo. 1 (1996) 15(24):6979–6990.
   Google Scholar
• HUANG DC, CORY S, STRASSER A: BCL-2, BCL-XL and adenovirus protein E1B19kD are functionally equiva-lent in their ability to inhibit cell death. Oncogene (1997) 14(4):405–414.
   PubMed Web of Science ®Google Scholar
• FEIG BW, LU X, HUNT KK et al: Inhibition of thetranscription factor nuclear factor-kappa b by adenoviral-mediated expression of I kappa b a m results in tumour cell death. Surgery (19 9 9) 126(2)399–405.
   Google Scholar
• OKUYAMA T, LI XK, FUNESHIMA N et al.: Fas-mediatedapoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors. J. Gastroenterol. Hepatol. (1998) 13 (Suppl. ):113–118.
   Google Scholar
• ELSING A, BURGERT HG: The adenovirus E3/10.4k-14.5k proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc. Natl. Acad. ScL USA (1998) 95 (17): 10072–10077.
   Google Scholar
• LI Y, KANG J, HORWITZ MS: Interaction of anadenovirus E3 14.7-kilodalton protein with a novel tumour necrosis factor a-inducible cellular protein containing leucine zipper domains. Mol. Cell Biol. (1998) 18(3):1601–1610.
   Google Scholar
• SHISLER J, YANG C, WALTER B, WARE CF, GOODING LR:The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface fas (CD95) and resistance to fas-induced apoptosis. j Vim]. (1997) 71 (11):8299–8306.
   Google Scholar
• NISHITANI J, NISHINAKA T, CHENG CH, RONG W, YOKOYAMA KK, CHIU R: Recruitment of the retinoblas-toma protein to C-jun enhances transcription activity mediated through the Ap-1 binding site. J. Biol. Chem. (1999) 274(9):5454–5461.
   PubMed Web of Science ®Google Scholar
• LEI M, LIU Y, SAMUEL CE: Adenovirus VAI RNA antago-nizes the RNA-editing activity of the ADAR adenosine deaminase. Virology (1998) 245(2)188–196.
   Google Scholar
• GHADGE GD, MALHOTRA P, FURTADO MR, DHAR R, THIMMAPAYA B: In vitro analysis of virus-associated RNA I (VAI RNA): inhibition of the double-stranded RNA-activated protein kinase PKR by VAI RNA mutants correlates with the in vivo phenotype and the structural integrity of the central domain. J. Vim]. (1994) 68(7):4137–4151.
   Web of Science ®Google Scholar
• SIMARD C, LANGLOIS I, STYGER D et al. Sequence analysis of the UL39, UL38 and UL37 homologues of bovine herpesvirus 1 and expression studies of UL40 and UL39, the subunits of ribonucleotide reductase. Virology (1995) 2 12(2) 734–740
   Google Scholar
• HE B, GROSS M, ROIZMAN B: The 7(1)34.5 protein ofherpes simplex virus 1 complexes with protein phosphatase la to dephosphorylate the a subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. ScL USA (1997) 94(3):843–848.
   Google Scholar
• CASSADY KA, GROSS M, ROIZMAN B: The second-sitemutation in the herpes simplex virus recombinants lacking the 7134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2a. J. Vim]. (1998) 72(9):7005–7011.
   Google Scholar
• COFFEY MC, STRONG JE, FORSYTH PA, LEE PW: Reovirus therapy of tumours with activated ras pathway [see comments]. Science (1998) 282(5392)1332–1334.
   Google Scholar
• •Describes reovirus selectivity for tumours.
   Google Scholar
• YUE Z, SHATKIN AJ: Double-stranded RNA-dependent protein kinase (PKR) is regulated by reovirus structural proteins. Virology (1997) 234(2)364–371.
   Google Scholar
• LORENCE RM, KATUBIG BB, REICHARD KW et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. (1994) 54(23)6017–6021.
   Google Scholar
• LAKSHMI MS, SHERBET GV: Genetic recombination in human melanoma and astrocytoma cell lines involves oncogenes and growth factor genes. Clin. Exp. Metastasis (1990) 8(1):75–87.
   PubMed Web of Science ®Google Scholar
• YEW PR, BERK AJ: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (1992) 357(6373)82–85.
   Google Scholar
• YEW PR, LIU X, BERK AJ: Adenovirus ElB oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. (1994) 8(2):190–202.
   PubMed Web of Science ®Google Scholar
• GOODING LR, AQUINO L, DUERKSEN-HUGHES PJ et al:The ElB 19,000-molecular-weight protein of group C adenoviruses prevents tumour necrosis factor cytolysis of human cells but not of mouse cells. J. Vim]. (1991) 65(6):3083–3094.
   Web of Science ®Google Scholar
• GOODING LR, RANHEIM TS, TOLLEFSON AE et al. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumour necrosis factor. J. Virol. (1991) 65(8):4114–4123.
   PubMed Web of Science ®Google Scholar
• DOBNER T, HORIKOSHI N, RUBENWOLF S, SHENK T: Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumour suppressor. Science (1996) 272(5267):1470–1473.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON AE, SCARIA A, HERMISTON TW, RYERSE JS,WOLD U, WOLD WS: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. (1996) 70(4):2296–2306.
   Google Scholar
• TOLLEFSON AE, HERMISTON TW, LICHTENSTEIN DL et al. Forced degradation of fas inhibits apoptosis in adenovirus-infected cells. Nature (1 9 9 8) 392(6677)726–730.
   Google Scholar
• DESAI SY, PATEL RC, SEN GC, MALHOTRA P, GHADGEGD, THIMMAPAYA B: Activation of interferon-inducible 2'-5'-oligoadenylate synthetase by adenoviral VAI RNA. J. Biol. Chem. (1 9 9 5) 2 70(7):3454–3461.
   Google Scholar
• WHYTE P, BUCHKOVICH KJ, HOROWITZ JM et al.: Association between an oncogene and an anti-oncogene: the adenovirus ElA proteins bind to the retinoblastoma gene product. Nature (1988) 334(6178):124–129.
   PubMed Web of Science ®Google Scholar
• ••An important milestone in showing interactions betweenviral and cellular proteins.
   Google Scholar
• GOLDSTEIN DJ, WELLER SK: Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology (1988) 166(1):41–51.
   PubMed Web of Science ®Google Scholar
• ••A significant advance in the understanding of a mechanismof viral selectivity for tumours.
   Google Scholar
• COEN DM, KOSZ-VNENCHAK M, JACOBSON JG et al.: Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA (1989) 86(12)4736–4740.
   Google Scholar
• CHOU J, ROIZMAN B: The y 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis character-istic of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. USA (1992) 89(8):3266–3270.
   Google Scholar
• ••An important paper describing the function of ICP34.5.
   Google Scholar
• GOLDSTEIN DJ, WELLER SK: Herpes simplex virus type1-induced ribonucleotide reductase activity is dispen-sable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Vim]. (1988) 62(1):196–205.
   Web of Science ®Google Scholar
• LORENCE RM, REICHARD KW, KATUBIG BB et al.: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy [see comments]. J Nati Cancer Inst. (1994) 86(16):1228–1233.
   PubMed Web of Science ®Google Scholar
• SAVILLE MK, WATSON RJ: B-myb: a key regulator of the cell cycle. Adv. Cancer Res. (1998) 72:109–140.
   PubMed Web of Science ®Google Scholar
• SAVILLE MK, WATSON RJ: The cell-cycle regulated transcription factor B-myb is phosphorylated by cyclin a/cdk2 at sites that enhance its transactivation properties. Oncogene (1998) 17(202679–2689.
   Web of Science ®Google Scholar
• LAM, KS, WU J, LOU Q: Identification and characteriza-tion of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases. Int. J. Pept. Protein Res. (1995) 45(6):587–592.
   PubMedGoogle Scholar
• CHOU J, CHEN JJ, GROSS M, ROIZMAN B: Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor EIF-2 a and premature shutoff of protein synthesis after infection with y 134.5- mutants of herpes simplex virus 1. Proc. Natl Acad. ScL USA (1995) 92(23):10516–10520.
   Google Scholar
• ROIZMAN B, MARKOVITZ N: Herpes simplex virus virulence: the functions of the y (1)34.5 gene. J. Neurovirol (1997) 3 (Suppl. 0:1–2.
   Google Scholar
• CASSADY, KA, GROSS M, ROIZMAN B: The herpes simplex virus usl 1 protein effectively compensates for the 71(34.5) gene if present before activation of protein kinase r by precluding its phosphorylation and that of the a subunit of eukaryotic translation initiation factor 2.j Virol. (1998) 72(10:8620–8626.
   Google Scholar
• HE B, CHOU J, LIEBERMANN DA, HOFFMAN B, ROIZMAN B: The carboxyl terminus of the murine myd116 gene substitutes for the corresponding domain of the 7(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J. Vim]. (1996) 70(1):84–90.
   Google Scholar
• HILTON MJ, MOUNGHANE D, MCLEAN T et al.: Inductionby herpes simplex virus of free and heteromeric forms of E2F transcription factor. Virology (1 9 9 5) 213(2)624–638.
   Google Scholar
• ZHAO ZS, GRANUCCI F, YEH L, SCHAFFER PA, CANTOR H:Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection [see comments]. Science (1998) 279(5355):1344–1347.
   PubMed Web of Science ®Google Scholar
• JAMIESON AT, GENTRY GA, SUBAK-SHARPE JH: Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. J. Gene Vim]. (1974) 24 (3):465–480.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, WELLER SK: An ICP6:lacZ insertionalmutagen is used to demonstrate that the U1L52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J. Virol. (1 9 8 8) 62(8)2970–2977.
   Google Scholar
• BOVIATSIS EJ, SCHARF JM, CHASE M et al.: Antitumouractivity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleo-tide reductase. Gene Ther. (1994) 1(5):323–331.
   PubMed Web of Science ®Google Scholar
• •Shows selective viral replication in rat brain tumours.
   Google Scholar
• BOVIATSIS EJ, CHASE M, WEI MX et al. Gene transfer into experimental brain tumours mediated by adenovirus, herpes simplex virus and retrovirus vectors. Hum. Gene Ther. (1994) 5 (2) 183–191
   PubMed Web of Science ®Google Scholar
• MINETA T, RABKIN SD, MARTUZA RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. (1994) 54(15):3963–3966.
   PubMed Web of Science ®Google Scholar
• MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. (1995) 1 (9)938–943.
   Google Scholar
• •Describes the first HSV mutant used in clinical trials.
   Google Scholar
• CARROLL NM, CHIOCCA EA, TAKAHASHI K, TANABE KK: Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg. (1996) 224(3):323–9.
   PubMed Web of Science ®Google Scholar
• BROWN SM, MACLEAN AR, MCKIE EA, HARLAND J: The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyoD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyoD116 and GADD34. Virol. (1997) 7i(12):9442–9449.
   Google Scholar
• MARKERT JM, MALICK A, COEN DM, MARTUZA RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (1993) 32(4)597–603.
   Google Scholar
• ANDREANSKY SS, HE B, GILLESPIE GY et al.: The applica-tion of genetically engineered herpes simplex viruses to the treatment of experimental brain tumours. Proc. Nati Acad. Sci. USA (1996) 93(20:11313–11318.
   PubMed Web of Science ®Google Scholar
• KESARI S, LASNER TM, BALSARA KR et al.: A neuroattenu-ated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol (1998) 79\(pt 3):525–536.
   Google Scholar
• KESARI S, RANDAZZO BP, VALYI-NAGY T et al: Therapy of experimental human brain tumours using a neuroattenuated herpes simplex virus mutant. Lab. Invest. (1995) 73(5):636–648.
   PubMed Web of Science ®Google Scholar
• KUCHARCZUK JC, RANDAZZO B, CHANG MY et al: Use of a 'replication-restricted' herpes virus to treat experi-mental human malignant mesothelioma. Cancer Res. (1997) 57(3):466–471.
   PubMed Web of Science ®Google Scholar
• COUKOS G, MAKRIGIANNAKIS A, KANG EH et al.: Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the 1P. Therapy of epithe-lial ovarian cancer. Clin. Cancer Res. (1999) 5(6):1523–1537.
   PubMed Web of Science ®Google Scholar
• COOPER J, CONNER J, CLEMENTS JB: Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase. j Virol. (1995) 69(8):4979–4985.
   PubMed Web of Science ®Google Scholar
• TODA M, RABKIN SD, MARTUZA RL: Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. (1998) 9(15)2177–2185.
   Google Scholar
• WALKER JR, MCGEAGH KG, SUNDARESAN P et al: Local and systemic therapy of human prostate adenocarci-noma with the conditionally replicating herpes simplex virus vector G207 [in process citation]. Hum. Gene Ther. (1999) 10(13):2237–2243.
   PubMed Web of Science ®Google Scholar
• KOOBY DA, CAREW JF, HALTERMAN MW et al: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). Faseb. J. (1999) 13(10:1325–1334.
   PubMed Web of Science ®Google Scholar
• PYLES RB, WARNICK RE, CHALK CL, SZANTI BE, PARYSEK LM: A novel multiply-mutated HSV-1 strain for the treatment of human brain tumours. Hum. Gene Ther. (1997) 8(5):533–544.
   PubMed Web of Science ®Google Scholar
• BOURSNELL ME, ENTWISLE C, ALT SA et al: Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer. Adv. Exp. Med Biol. (1998) 451:379–384.
   PubMed Web of Science ®Google Scholar
• DILLOO D, RILL D, ENTWISTLE C et al.: A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood (1997) 89(1):119–127.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI D, OGRYZKO V, KAO HY et al.: A viral mechanism for inhibition of p300 and PCAF acetyl-transferase activity. Cell (1999) 96(3):393–403.
   PubMed Web of Science ®Google Scholar
• TODRYK S, MCLEAN C, ALI S: Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum. Gene. Ther. (1999) 10(17)2757–68
   Google Scholar
• ROIZMAN B, SEARS AE: Herpes simply viruses and their replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM (Eds.) 3rd Edition. Lippincott-Raven Publishers, Philadelphia, USA (1996) 8(2)2950–2997.
   Google Scholar
• KAO CC, YEW PR, BERK AJ: Domains required for in vitro association between the cellular p53 and the adenovirus 2 ElB 55K proteins. Virology (1990) 179(2):806–814.
   PubMed Web of Science ®Google Scholar
• KIRN D, HERMISTON T, MCCORMICK F, ONYX-015: clinical data are encouraging [letter; comment]. Nature Med. (1998) 4(12):1341–1342.
   PubMed Web of Science ®Google Scholar
• •Useful summary of clinical results thus far.
   Google Scholar
• ROTHMANN T, HENGSTERMANN A, WHITAKER NJ, SCHEFFNER M, ZUR HAUSEN H et al.: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumour cells. J. Vim]. (1998) 72(12):9470–9478.
   Google Scholar
• GOODRUM FD, ORNELLES DA: The early region lb 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Vim]. (1997) 71 (1):548–561.
   Web of Science ®Google Scholar
• GOODRUM FD, ORNELLES DA: p53 status does not determine outcome of ElB 55-kilodalton mutant adenovirus lytic infection. J. Virol. (1998) 72(12)9479–9490.
   Google Scholar
• VOLLMER CM, RIBAS A, BUTTERFIELD LH et al. P53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. (1999) 59(17):4369–4374.
   PubMed Web of Science ®Google Scholar
• YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumour xenografts. Cancer Res. (1999) 59(17)4200–4203.
   Google Scholar
• RODRIGUEZ R, SCHUUR ER, LIM HY et al.: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57(13):2559–2563.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, LAI S, LOU YC, JAN HY, FANG X, ZHANG WW: Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. (1999) 6 (0 :21–25.
   PubMed Web of Science ®Google Scholar
• KLEIN PA: Antibody-mediated immunity to transplant-able tumours following reovirus oncolysis. Pathol. Microbic)]. (1967) 30(2):222–245.
   PubMed Web of Science ®Google Scholar
• BRYSON JS COX DC: Characteristics of reovirus-mediated chemoimmunotherapy of murine 11210 leukemia. Cancer. Immunol Immunother. (1988) 26(2):132–138.
   PubMed Web of Science ®Google Scholar
• STEELE TA, COX DC: Reovirus type 3 chemoimmuno-therapy of murine lymphoma is abrogated by cyclosporin. Cancer Biother. (1995) 10 (4):307–315.
   PubMedGoogle Scholar
• LU Y, WAMBACH M, KATZE MG, KRUG RM: Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the eLF-2 translation initiation factor. Virology (1995) 214(0:222–228.
   PubMed Web of Science ®Google Scholar
• KATZE MG: Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol. (1995) 3(2)75–78.
   Google Scholar
• GALE M, JR, KATZE MG: Molecular mechanisms of interferon resistance mediated by viral- directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther. (1998) 78 (1) :29–46.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL, WELLS M: Curability of tumours bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl. Cancer Inst. (1990) 82 (4) 297–300.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Tumour chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46(105276–5281.
   Web of Science ®Google Scholar
• BOVIATSIS EJ, PARK JS, SENA-ESTEVES M: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. (1994) 54(22):5745–51.
   PubMed Web of Science ®Google Scholar
• CARROLL NM, CHASE M, CHIOCCA EA, TANABE KK: The effect of ganciclovir on herpes simplex virus-mediated oncolysis. j Surg. Res. (1997) 69(2):413–417.
   PubMed Web of Science ®Google Scholar
• YOON SS, CARROLL NM, CHIOCCA EA, TANABE KK: Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector [published erratum appears in Ann. Surg. 1998 nov; 228(5):following table of contents]. Ann. Surg. (1998) 228(3):366–374.
   Google Scholar
• WET MX, TAMIYA T, CHASE M et al: Experimental tumour therapy in mice using the cyclophosphamide-activating cytochrome p450 2B1 gene. Hum. Gene Ther. (1994) 5(8)969–978.
   Google Scholar
• WET MX, TAMIYA T, RHEE RJ, BREAKEFIELD XO, CHIOCCA EA: Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome p450 2B1 cancer gene therapy paradigm. Clin. Cancer Res. (1995) 1(101171–1177.
   Web of Science ®Google Scholar
• CHEN L, WAXMAN DJ: Intratumoural activation and enhanced chemotherapeutic effect of oxazaphos-phorines following cytochrome p450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. CancerRes. (1995) 55(3) :581–589.
   Web of Science ®Google Scholar
• AGHI M, CHOU TC, SULING K, BREAKEFIELD XO, CHIOCCA EA: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome p450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. (1999) 59(16):3861–3865.
   PubMed Web of Science ®Google Scholar
• FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene and radiotherapy [see comments]. Hum. Gene Ther. (1998) 9(9):1323–1333.
   PubMed Web of Science ®Google Scholar
• ANDREANSKY S, HE B, VAN COTT J et al.: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. (1998) 5(0:121–130.
   Google Scholar
• ZHANG JF, HU C, GENG Y et al.: Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regres-sion due to viral oncolysis and gene therapy. Proc. NatI Acad. Sci. USA (1996) 93(9):4513–4518.
   PubMed Web of Science ®Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al: ONYX-015, an ElB gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nature Med. (1997) 3(6)639–645.
   Google Scholar
• •Demonstrates the usefulness of combined therapeutic approaches using oncolytic viruses.
   Google Scholar
• ADVANI SJ, SIBLEY GS, SONG PY et al.: Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumours. Gene Ther. (1998) 5 (2): 160–165.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the usefullness of combination therapy.
   Google Scholar
• CHAHLAVI A et al.: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1:162.
   PubMedGoogle Scholar